文献速递银屑病与炎症性皮肤病

Envudeucitinib治疗中重度斑块状银屑病52周开放扩展期安全性与疗效

Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.
PubMed 文献 · J Am Acad Dermatol · 2025-10-06

STRIDE 2期研究完成后,165例患者进入开放标签扩展期,接受 envudeucitinib 40mg 每日一次或两次。治疗52周时,每日两次组 PASI-75、PASI-90、PASI-100 和 sPGA-0 应答率分别为78%、61%、39%和39%,药物总体耐受良好,因不良事件停药率3.7%,无临床关注的实验室或心电图异常。

要点

  • 每日两次组52周PASI-75应答率78%,PASI-90为61%。
  • 39%患者达到PASI-100和sPGA-0,62%较12周持续改善。
  • 因不良事件停药率3.7%,无临床关注实验室或心电图异常。

核心结论

  • Envudeucitinib 40mg每日两次在中重度斑块状银屑病成人中52周内皮肤清除和瘙痒持续改善且耐受良好。

研究设计与样本

  • STRIDE 2期研究完成后开展的开放标签扩展研究(NCT05739435),纳入165例患者,接受 envudeucitinib 40mg 每日一次或两次。

主要发现

  • 每日两次组52周时78%达到PASI-75、61%达到PASI-90、39%达到PASI-100、39%达到sPGA-0。
  • 62%患者PASI应答较STRIDE第12周持续改善。
  • 约80%报告瘙痒NRS<4,61%达到DLQI 0/1。
  • 总体因不良事件停药率3.7%,无临床关注的实验室或心电图发现。

临床怎么用

  • 52周数据支持 envudeucitinib 每日两次用于中重度斑块状银屑病长期治疗耐受性良好且疗效随治疗时间增加。

局限性

  • 开放标签研究,样本量有限且无对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Envudeucitinib (ESK-001), a highly selective, oral tyrosine kinase 2 inhibitor, was well-tolerated and effective in patients with plaque psoriasis in the STRIDE study. OBJECTIVE: To assess long-term safety and efficacy of envudeucitinib throughout 52 weeks in the ongoing phase 2 open-label extension in patients who completed STRIDE. METHODS: Patients completing STRIDE were eligible to enroll in the long-term open-label extension study (NCT05739435) and received envudeucitinib 40-mg once or twice daily. RESULTS: In the open-label extension which enrolled 165 patients, envudeucitinib was generally well-tolerated, with an overall 3.7% study drug discontinuation rate due to adverse events, as well as no clinically concerning laboratory or electrocardiogram findings. After 52 weeks of treatment with envudeucitinib 40-mg twice daily, 78% of patients achieved Psoriasis Area and Severity Index (PASI)-75, 61% achieved PASI-90, 39% achieved PASI-100, and 39% achieved sPGA-0. Moreover, 62% showed continued improvement in PASI response over time versus STRIDE week 12. In addition, approximately 80% reported pruritus Numerical Rating Scale <4 and 61% achieved Dermatology Life Quality Index 0/1. LIMITATIONS: This was an open-label study with limited sample size and no control. CONCLUSION: Envudeucitinib 40-mg twice daily in adults with moderate-to-severe plaque psoriasis demonstrated increasing and durable improvements in skin clearance and pruritus and was well-tolerated throughout 52 weeks of treatment.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Papp KA, Jacobs S, Sofen H, et al. Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study. J Am Acad Dermatol. 2025. PMID: 41061968. doi:10.1016/j.jaad.2025.10.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。